Skip to content

    Psoriasis Health Center

    Font Size

    New Psoriasis Drug Passes Hurdle

    Drug Hailed for Treating Moderate to Severe Plaque Psoriasis
    WebMD Health News
    Reviewed by Louise Chang, MD

    April 17, 2008 -- A novel immune-suppressing drug appears to effectively treat moderate to severe plaque psoriasis, according to a new report published in The Lancet.

    Psoriasis is a chronic inflammatory skin condition that affects about 7.5 million Americans, according to the National Institutes of Health. Plaque psoriasis is the most common type of psoriasis.

    Cyclosporin, a type of drug called a calcineurin inhibitor, is among the most effective short-term treatments for plaque psoriasis. However, concerns that the drug can lead to kidney damage has limited its long-term use. Newer drugs offer alternatives, but they are often cost prohibitive, and few data exist on their long-term safety and effectiveness.

    ISA247 is a new type of calcineurin inhibitor taken by mouth that is designed to treat autoimmune conditions, including psoriasis. Canada-based researcher Kim Papp and colleagues evaluated the drug's effectiveness in a phase III clinical trial involving 451 patients 18 to 65 years old. To be eligible for the study, the patient had to have plaque psoriasis on at least 10% of their body.

    Papp's team divided the patients into four groups and randomly assigned them to different doses of the medication or a placebo. The study participants took the medicine twice a day.

    Researchers considered the drug effective if it caused a 75% reduction in the psoriasis area and severity index score (PASI 75) at week 12.

    At 12 weeks, researchers found that the higher the dose of ISA247, the better it performed. The drug was effective in 47% of those who received the highest dose, compared with only 16% of those on the lowest dose and 4% in the placebo group. After following participants for another 12 weeks, the researchers demonstrated continued efficacy.

    The researchers noted temporary mild to moderate reduction in kidney function in some patients in the study. The most common adverse events were headache, upper respiratory tract infection, and inflammation of the nose and throat.

    (How are you currently treating your psoriasis? Is it effective? Talk with others on WebMD's Skin Care: Share Your Tips message board.)

    Today on WebMD

    Woman sitting in front of UV lights
    About 7.5 million people in the U.S. Get the facts.
    stress and psoriasis
    What might spark your psoriasis today?
    woman bathing
    Slideshow: Home Remedies For Psoriasis
    woman applying lotion
    It starts in the immune system. Read on.
    Top Psoriasis Treatments To Try At Home
    Woman sitting in front of UV lights
    Beware Miracle Diets For Psoriasis
    Psoriasis Laser Therapy
    10 Questions About Psoriasis To Ask Your Doctor
    psoriasis on elbow
    Psoriasis (Moderate to Severe)
    Psoriatic Arthritis Do You Know The Symptoms